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OBJECTIVES We sought to use positron emission tomography (PET) to test the hypothesis that
hyperhomocysteinemia adversely effects coronary microvascular dilator function.
BACKGROUND Hyperhomocysteinemia is associated with abnormal endothelium-dependent vasodilation in
peripheral human arteries. However, its effect on the coronary circulation is not known.
METHODS Eighteen healthy humans, age 24 to 56 years, were enrolled in a double-blind, crossover trial.
Basal and adenosine-stimulated myocardial blood flow (MBF) was determined by PET: after
ingestion of placebo and after methionine-induced hyperhomocysteinemia. Further, brachial
ultrasonography was used to assess flow-mediated vasodilation. Additionally, to assess the
role of nitric oxide (NO) in adenosine-mediated vasodilation, the MBF response to adenosine
was measured in the presence and absence of the NO synthase antagonist NG-monomethyl-
L-arginine (L-NMMA) (0.3 mg/kg/min intravenously).
RESULTS Hyperhomocysteinemia resulted in a reduction in the MBF dose-response curve to adenosine
(p  0.05). This was most apparent with low dose adenosine, where MBF augmentation was
significantly blunted during hyperhomocysteinemia (1.06  1.00 ml/min/g vs. 0.58  0.78
ml/min/g, placebo vs. methionine, p  0.05). Similarly, flow-mediated brachial artery
vasodilation was impaired during hyperhomocysteinemia (4.4 2.6% vs. 2.6 2.3%, placebo
vs. methionine, p  0.05). In a separate series of experiments, MBF during adenosine was
reduced in the presence of L-NMMA (p 0.05 analysis of variance). This was most apparent
at the low dose of adenosine, where MBF response to adenosine was blunted in the presence
of L-NMMA (2.08  1.34 ml/min/g vs. 1.48  1.32 ml/min/g, placebo vs. L-NMMA, p 
0.05).
CONCLUSIONS The data, therefore, support the hypothesis that acute hyperhomocysteinemia impairs
microvascular dilation in the human coronary circulation as a result of reduced NO
bioavailability. (J Am Coll Cardiol 2002;40:1051–8) © 2002 by the American College of
Cardiology Foundation
Prospective and case-controlled studies have demonstrated
that elevations in plasma homocysteine levels are associated
with an increased risk of cardiovascular diseases, including
myocardial infarction (1–5). This may be an issue of
significant clinical relevance, since elevations in plasma
homocysteine are common, affecting approximately 10% of
the general population and over 40% of individuals with
coronary artery disease (2–5).
We previously demonstrated impaired flow-mediated
vasodilation of the brachial artery in chronically hyperho-
mocysteinemic, but otherwise healthy humans; an observa-
tion that suggests nitric oxide (NO) bioavailability is de-
creased in those individuals (6). Others have since shown
that flow-mediated vasodilation is acutely impaired after the
induction of acute hyperhomocysteinemia with methionine
(7–9). It is not known whether these homocysteine-
associated, peripheral arterial blood flow abnormalities are
relevant to the human coronary circulation. Therefore, the
present study was designed to test the hypothesis that acute
hyperhomocysteinemia impairs the vasodilator function of
the coronary microcirculation. We employed positron emis-
sion tomography (PET) to assess the coronary microvascu-
lar dilator response to low and high dose adenosine in
healthy humans in whom we induced transient hyperhomo-
cysteinemia via oral “loading” with the essential amino acid,
methionine. Furthermore, to demonstrate that adenosine-
induced coronary microvascular dilation is in part mediated
by NO, a separate series of experiments was conducted
during which the myocardial blood flow (MBF) response to
adenosine 70 and 140 g/kg/min was measured in the
presence and absence of the systemic infusion of the nitric
oxide synthase (NOS) antagonist, NG-monomethyl-L-
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arginine (L-NMMA) (0.3 mg/kg/min). Additionally, bra-
chial ultrasonography was used to measure flow-mediated
vasodilatation in order to assess the relevance of peripheral
vascular dilator function to the coronary microcirculation in
the same patient population.
METHODS
Patient population. A total of 18 healthy subjects (13
males) age 40  10 years (mean  SD) were recruited from
the greater Boston area. Subjects were entered into one or
more of three substudies that: 1) assessed the effect of
transient hyperhomocysteinemia on coronary microvascular
dilation (n  15 subjects); 2) assessed the contribution of
NO to adenosine mediated coronary vasodilation (n  12
subjects); or 3) assessed the effect of transient hyperhomo-
cysteinemia on flow mediated dilation of the brachial artery
(n  12 subjects). Because of the demanding nature of the
study, only eight subjects participated in all three protocols.
Exclusion criteria included the following: smoking; systolic
blood pressure (SBP) 140 mm Hg or diastolic blood
pressure 90 mm Hg; serum cholesterol level above the
75th percentile for age and gender; history of vascular
disease; diabetes; family history of premature coronary
artery disease; or any clinical manifestation coronary artery
disease, peripheral artery disease, or carotid artery disease.
The study protocol was approved by the Joint Human
Research Committee of the Massachusetts General Hospi-
tal and Brigham and Women’s Hospital, and informed
consent was obtained from each subject.
Protocol 1: homocysteine and coronary microvascular
dilation. The effect of transient hyperhomocysteinemia on
coronary microvascular dilation was assessed in 15 subjects
(age 37  3 years, 10 male). Using a double-blinded,
placebo-controlled crossover design, methionine powder
(100 mg/kg) (Ajinimoto Pharmaceuticals) versus a similar
appearing placebo (dextrose) was mixed in juice and admin-
istered orally 8 to 10 h prior to blood flow measurements.
Such “methionine loading” produces transient hyperhomo-
cysteinemia by metabolically stressing homocysteine metab-
olism and has been used extensively and safely (10).
MBF measurements. Basal and adenosine-stimulated
MBF was assessed with PET 8 to 10 h after ingestion of
methionine versus placebo. Positron emission tomography
measurements of MBF are highly reproducible and correlate
well with MBF determined using radiolabeled microspheres
(11–13). We and others have shown that one standard
deviation for blood flow measurements in the same patient
under comparable circumstances is 0.1 to 0.2 ml/min/g
(14,15). Furthermore, this technique has been used by our
group to demonstrate improvement in coronary microvas-
cular dilation response after lipid lowering therapy (15), (a
treatment that improves NO bioavailability).
Adenosine dose response curve. Positron emission tomo-
graphic imaging is performed on a whole body tomograph
(GE Medical Systems Scanditronix PC4096) in subjects
after an overnight fast using a previously described protocol
(15,16). Briefly, images are acquired in 15 contiguous
sections simultaneously with center-to-center separation of
6.5 mm. First, a 10-min transmission scan is performed to
correct the emission data for attenuation. Next, three
dynamic tomographic acquisitions are performed: at rest,
and during two separate intravenous infusions of adenosine
(70 and 140 g/kg/min, from 2 min before to 4 min after
initiation of image acquisition). Approximately 25 mCi of
13N-ammonia is administered for each acquisition, with
imaging begun just prior to injection. Data are collected for
the first 3 min at 6 s/frame and then at 2 min/frame for 6
min. After each image acquisition, radioactivity is allowed
to decay for approximately 30 to 40 min, at which time the
count rate seen by the scanner is approximately 7500/s and
is effectively overwhelmed by the next dose. The patient’s
heart rate (HR) and electrocardiogram is monitored con-
tinuously during and following PET blood flow measure-
ments and arterial pressure determined by cuff at 1 to 2 min
intervals. An interval of at least one week was allowed
between each study visit.
PET image analysis. Attenuation-corrected 13N-ammonia
images are reconstructed with a conventional filtered back
projection algorithm as 128  128 pixel images in the
transverse plane normal to the long axis of the body.
Filtering of the projection data is performed with a Hanning
filter to yield output resolution of 7.8 mm full width at half
maximum. The 13N-ammonia scans (n  3), for each
patient corresponding to the last 6 min of data acquisition,
are summed to permit placement of a region of interest over
the left ventricular cavity. The region of interest is used to
generate the arterial input function for the tracer kinetic
model by which regional myocardial blood flow is deter-
mined. A computer program developed at our institution is
used in conjunction with the dynamic data to generate
parametric (K1) images. The images obtained provide a
pixel-by-pixel representation of K1 and are used for analysis
of regional MBF.
Three short axis rings corresponding to the proximal,
middle and distal thirds of the left ventricle were con-
structed for each K1 scan as described previously (15).
Abbreviations and Acronyms
ADMA  asymmetric dimethylarginine
G  myocardial conductance
HR  heart rate
L-NMMA  NG-monomethyl-L-arginine
MAP  mean arterial pressure
MBF  myocardial blood flow
METH  methionine-induced hyperhomocysteinemia
NO  nitric oxide
NOS  nitric oxide synthase
PET  positron emission tomography
RPP  rate-pressure product
SBP  systolic blood pressure
1052 Tawakol et al. JACC Vol. 40, No. 6, 2002
Homocysteine Impairs Coronary Vasodilation in Humans September 18, 2002:1051–8
Briefly, circular regions of interest (8.5 mm radius) were
placed over each ring at standard areas of interest: infero-
septum, mid-septum, anteroseptum, anterior, anterolateral,
lateral, posterolateral, and inferior zones. Myocardial blood
flow was computed from values of K1 and averaged over all
regions to obtain a single value blood flow used each
experimental condition. Myocardial conductance (G) was
computed by dividing myocardial blood flow by mean
arterial pressure. Mean arterial pressure (MAP) was com-
puted as follows: MAP  diastolic arterial pressure 
(0.333  pulse pressure). Rate-pressure product (RPP) is
calculated: RPP  HR  SBP.
Protocol 2: assessment of the contribution of NO to
adenosine mediated coronary vasodilation. The contri-
bution of NO in adenosine-mediated vasodilation was
assessed in a subset of 12 subjects (8 males, age 41  2.7
years). Eight of those subjects had previously participated in
the first protocol. Subjects were entered in a placebo-
controlled crossover experiment, during which the NOS
antagonist, L-NMMA (Clinalpha, Switzerland) versus nor-
mal saline was infused before MBF measurements (at rest
and during the infusion of adenosine at 70 and 140
g/kg/min). The L-NMMA was infused intravenously at
0.3 mg/kg/min for 16 min (10 min before and 6 min
during) each of the three measurements of MBF. The total
cumulative dose of L-NMMA administered to each subject
was therefore approximately 14. 5 mg/kg (0.3 mg/kg/min
16 min  3 infusions). The dose of L-NMMA was chosen
based on prior human experiments (17). Resting and
adenosine-stimulated blood flow measurements were ob-
tained using PET as described previously.
Protocol 3: homocysteine and brachial artery flow-
mediated vasodilation. Twelve subjects who underwent
PET imaging after methionine loading, agreed to undergo
assessment of peripheral vascular function after ingesting
methionine versus placebo. Eight to ten hours after methi-
onine ingestion, flow-mediated vasodilation was assessed by
high-resolution ultrasonography, a technique that has been
described previously and validated (16,18). Longitudinal
images of the brachial artery were obtained 10 to 80 mm
proximal to the antecubital fossa by use of a Toshiba model
270 SSA scanner (Tochigi-ken, Japan) equipped with a
7.5-MHz high-resolution linear-array transducer. Flow-
mediated vasodilation was assessed by measuring the per-
cent change from baseline of brachial artery diameter during
reactive hyperemia. Flow-mediated vasodilation of periph-
eral conduit vessels is largely an endothelium-dependent
process, mediated by nitric oxide and inhibited by
L-NMMA (18). Furthermore, flow-mediated vasodilation
of peripheral conduit vessels correlates with acetylcholine-
stimulated, NO-mediated dilation of epicardial coronary
arteries in humans (16). To stimulate flow-mediated vaso-
dilation, a pneumatic cuff was placed on the forearm and
inflated to suprasystolic pressures for 5 min. Thereafter, the
brachial artery was imaged after cuff deflation, and images
were acquired for analysis at 1 min after cuff deflation.
Time-averaged flow velocity integral was recorded. In nine
subjects, brachial artery scanning was repeated after 0.4 mg
sublingual nitroglycerin (10 min after flow-mediated vaso-
dilation) to assess endothelium-independent vasodilation.
The artery was scanned for an additional 3 min, at which
time images were once again acquired for digitization and
measurement. Blood pressure and HR were monitored
during this procedure.
An investigator blinded to the subjects’ study drug order
analyzed the end-diastolic images for each condition (base-
line, reactive hyperemia, repeat baseline, nitroglycerin),
using software (Information Integrity) that searched for the
shortest distance between the points on the arterial wall.
Arterial diameter was measured from the intima-media
interface of the posterior wall to the media-adventitia
interface of the anterior wall. The average of three measure-
ments was used for each determination of brachial artery
diameter.
Biochemical measurements. Blood samples were obtained
at the time of blood flow measurements. Samples were
promptly spun, separated, frozen and stored at 70°C.
Measurement of homocysteine and methionine were per-
formed at the Mayo Clinic Laboratories (Rochester, Min-
nesota) using previously described methods (19). Plasma
isoprostane concentration, an indicator of lipid peroxidation
(20), was measured using previously described methods
(20). Plasma concentrations of asymmetric dimethyl-
arginine (ADMA) were measured by high-performance
liquid chromatography using modifications of previously
described methods (21).
Statistical analysis. Data are expressed as mean  SD.
The significance of changes in group mean values of MBF
and MBF ratio were assessed with factorial analysis of
variance (ANOVA) and Fisher’s protected least significant
difference test (Statview v4.0, Abacus Concepts). Wilcoxon
Signed Rank tests were used to evaluate the significance of
difference in brachial artery vasodilation, hemodynamics,
and biochemical variables. Linear regression analysis was
used to assess the relationship between group mean values of
G and adenosine dose before and after methionine. A paired
t test was also employed to assess the significance of the
change in percent change (from baseline) in MBF at
adenosine 70 (placebo vs. methionine). Log10 transforma-
tion of the blood flow data was applied to reduce statistical
noise. Values of p  0.05 were considered significant.
RESULTS
Biochemical changes. The mean fasting plasma homocys-
teine concentrations were 8.3  2.7 mol/l after placebo
and 27.1  11.2 mol/l after methionine (p  0.001). The
mean fasting plasma methionine concentrations were 25 
4 and 335  215 l after placebo and methionine, respec-
tively (p  0.001). Plasma isoprostane concentrations did
not significantly change after methionine versus placebo
(37.1  9.3 vs. 56.6  15.9 pg/ml, respectively, p  NS).
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ADMA did not change after methionine versus placebo
(1.1  0.2 vs. 1.1  0.4 l, respectively, p  NS).
Dynamics during PET. During the placebo condition, at
rest, the HR was 59 8 min1, MAP was 85 9 mm Hg,
and RPP was 6,700 1,051 mm Hgmin1. While none
of these hemodynamic parameters changed after the admin-
istration of adenosine 70, adenosine 140 caused an increase
in HR (to 89 20 min1) and RPP (to 9,935 2,657 mm
Hg  min1). There were no significant changes in HR,
blood pressure, or RPP between the methionine and pla-
cebo conditions (either at rest or during adenosine 70 or
140).
MBF and G. At rest, MBF and G did not differ signifi-
cantly between control and methionine conditions. In re-
sponse to adenosine, there was a dose dependent, graded
increase over baseline in MBF after placebo and methionine
loading. The changes in flow from baseline to intermediate
dose and from intermediate to high dose were all statistically
significant for both placebo and methionine (Table 1).
During methionine-induced hyperhomocysteinemia
(METH), the MBF response to adenosine was reduced
compared with placebo (p  0.05, ANOVA, Fig. 1A).
Furthermore, MBF augmentation (adenosine MBF base-
line MBF) to low dose adenosine was blunted during
METH (1.06  1.01 vs. 0.58  0.78 placebo vs. methio-
nine, p  0.05, Fig. 1B). As such, during hyperhomocys-
teinemia, there was a 45% reduction in MBF augmentation
with the 70 g/kg/min dose of adenosine (vs. placebo).
Furthermore, flow augmentation to low dose adenosine was
inversely related to the concentration of plasma homocys-
teine (r  0.38; p  0.05). In contrast, there was no
significant association between the MBF response to aden-
osine and the concentration of methionine.
Conductance changes paralleled those of MBF. Thus,
there was a consistent, highly significant (p  0.001) dose
dependent, increase in conductance with each dose of
adenosine under control conditions. In contrast, after me-
thionine, the increase in conductance at intermediate aden-
osine was blunted and failed to reach statistical significance.
The effect of NOS inhibition on resting and adenosine-
augmented MBF. During L-NMMA, no symptoms or
electrocardiographic signs of ischemia were observed in any
subject. The hemodynamic effects of L-NMMA were evi-
denced by an increase in SBP and MAP and decline in HR
versus placebo (all p  0.05) (Table 2). The RPP did not
change versus placebo.
At rest, NO inhibition (with L-NMMA) did not affect
MBF. However, L-NMMA reduced the MBF response to
Table 1. Effect of Methionine on Myocardial Blood Flow and Conductance (Mean  SD)
Baseline Ado 70 Ado 140
MBF (ml/min/g)
Placebo 0.70  0.19 1.75  1.13† 3.51  0.84‡
Methionine 0.76  0.36 1.34  0.26 3.76  1.00‡
Ratio (METH:Placebo) 1.09  0.28 0.86  0.48* 1.11  0.33
G (ml/min/g/mm Hg)
Placebo 8.30  2.53 21.79  15.29‡ 45.69  13.97‡
Methionine 8.94  3.52 15.97  12.04 47.23  12.60‡
Ratio (METH:Placebo) 1.11  0.07 0.87  0.13* 1.11  0.10
*p  0.05 vs. baseline and Ado 140; †p  0.05 vs. baseline; ‡p  0.005 vs. baseline.
Ado 70  adenosine 70 g/kg/min; Ado 140  adenosine 140 g/kg/min; G  myocardial conductance; MBF 
myocardial blood flow; METH  methionine condition.
Figure 1. (A) Effect of acute hyperhomocysteinemia on the myocardial blood flow (MBF) response to adenosine. This figure depicts MBF at rest and during
infusion of low and high dose adenosine, after placebo and during methionine-induced hyperhomocysteinemia (METH). The adenosine dose response
curve is significantly impaired during methionine vs. placebo (p  0.05, ANOVA). (B) Acute hyperhomocysteinemia impairs the coronary microvascular
dilator response to adenosine. This figure depicts the MBF response to the low and high doses of adenosine. The coronary microvascular dilator response
to low dose adenosine was significantly blunted during METH (p  0.05). In contrast, the microvascular dilator response to high dose adenosine was
unaffected.
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adenosine (p  0.05 ANOVA) (Fig. 2). This is attributed
to L-NMMA’s effect on MBF during infusion of the
adenosine 70 dose (2.07 1.33 vs. 1.48 1.32 ml/gm/min,
placebo vs. L-NMMA, p  0.05) (Fig. 2A). In contrast to
that, L-NMMA did not significantly reduce the MBF
response to the adenosine 140 dose (3.65  0.65 vs. 3.36 
0.83 ml/gm/min, placebo vs. L-NMMA, p  NS). However,
L-NMMA reduced conductance during both doses of adeno-
sine (25.51 17.42 vs. 16.07 15.30, and 47.72 12.12 vs.
35.60  9.81 ml/min/gm/mm Hg for placebo vs. L-NMMA,
adenosine 70 and 140, respectively, p  0.05) (Fig. 2B).
Peripheral vascular function. The time-averaged flow ve-
locity integral during peak reactive hyperemia, a measure of
the stimulus for flow-mediated vasodilation, was the same
for both groups (36.2 8.7 vs. 36.5 4.2 cm/s, placebo vs.
methionine, respectively; p  NS). Flow-mediated,
endothelium-dependent vasodilation was significantly de-
creased during hyperhomocysteinemia compared with the
control state (4.4  2.6% vs. 2.6  2.3%, placebo vs.
methionine, p  0.05), demonstrating that the bioavailabil-
ity of NO is decreased during acute hyperhomocysteinemia.
However, endothelium-independent vasodilation to sublin-
gual nitroglycerin was preserved (20.0  6.1% vs. 20.2 
5.1%, placebo vs. methionine; p  NS), demonstrating
normal vasodilation in response to the administration of a
NO donor. Furthermore, flow-mediated vasodilation cor-
related with plasma homocysteine concentration (r 
0.50, p  0.05).
Table 2. Effect of L-NMMA on Myocardial Blood Flow and Hemodynamic Variables (Mean 
SD)
Baseline Ado 70 Ado 140
Placebo
MBF 0.67  0.20 2.08  1.34*† 3.65  0.65†
G 7.72  2.39 25.51  17.42*† 47.72  12.12*†
HR 60  9* 68  14* 90  19*
MAP 87  42* 84  8* 78  10*
RPP 6,926  1,331 7,811  1,789 9,848  2,445
L-NMMA
MBF 0.63  0.23 1.48  1.32† 3.36  0.83†
G 6.69  2.36 16.07  15.30† 35.60  9.81†
HR 53  10 54  17 68  24
MAP 94  11 93  10 96  12
RPP 6,607  1,394 6,676  2,157 8,344  2,487
*p  0.05 (L-NMMA vs. placebo); †p  0.005 vs. baseline.
Ado 70  adenosine 70 g/kg/min; Ado 140  adenosine 140 g/kg/min; G  myocardial conductance, (ml/min/g/
mmHg); HR  heart rate (beats/min); L-NMMA  NG-monomethyl-L-arginine; MBF  myocardial blood flow, (ml/min/g);
RPP  rate pressure product (SAP  HR, expressed as mm Hg  beats/min); SAP, DAP, and MAP  systolic, diastolic, and
mean arterial pressure, respectively (mm Hg).
Figure 2. (A) Effect of nitric oxide inhibition on the myocardial blood flow (MBF) response to adenosine. This figure depicts the MBF at rest and during
low and high dose adenosine infusions, after placebo and during infusion of the nitric oxide synthase inhibitor, NG-monomethyl-L-arginine (L-NMMA).
The adenosine dose response curve is significantly impaired during L-NMMA vs. placebo (p  0.05, analysis of variance [ANOVA]). While nitric oxide
inhibition significantly reduced MBF to low-dose adenosine, the MBF response to high dose adenosine was unaffected. (B) Effect of nitric oxide inhibition
on the myocardial conductance response to adenosine. This figure depicts the myocardial conductance (G) at rest and during low and high dose adenosine
infusions, after placebo and during infusion of the nitric oxide synthase inhibitor, L-NMMA. The adenosine dose response curve is significantly impaired
during L-NMMA versus placebo (p  0.05, ANOVA). Nitric oxide inhibition significantly reduced conductance to both low- and high-dose adenosine.
1055JACC Vol. 40, No. 6, 2002 Tawakol et al.
September 18, 2002:1051–8 Homocysteine Impairs Coronary Vasodilation in Humans
DISCUSSION
The important new findings in this study are: 1) that
transient elevations in plasma homocysteine (to concentra-
tions that are commonly encountered in clinical practice) are
associated with acute impairment of the myocardial vasodi-
lator response to adenosine in healthy humans and, 2) that
the myocardial vasodilator response to adenosine is in part
mediated by NO release. Furthermore, the finding of
homocysteine-associated impairment in coronary microvas-
cular endothelium-dependent vasodilation is paralleled by
similar impairments in the peripheral circulation within the
same subjects. As such, this study extends the previous
findings of homocysteine-associated circulatory abnormali-
ties, for the first time, to the human coronary circulation.
Role of NO in adenosine-induced vasodilation. Data
from studies of the human peripheral circulation and from
animal models of the coronary circulation suggest that NO
release contributes to the vasodilator response to adenosine,
(22–25). In the present study, we demonstrate that the
coronary microvascular dilator response to adenosine is
reduced during co-administration of the NOS antagonist,
L-NMMA, (Figs. 2A and 2B, Table 2). As such, the data
support the hypothesis that adenosine’s effect on microvas-
cular dilation is at least in part dependent on NO bioavail-
ability.
The results of the present study are similar to those
recently reported by Buus et al. (25) in which NOS
inhibition with NG-nitro-L-arginine methyl ester reduced
the hyperemic response to adenosine by 21% from 1.90 to
1.50 ml/gm/min, p  0.05. In our study, we report that
L-NMMA reduced the hyperemic response to adenosine by
29% (from 2.07 to 1.49 ml/gm/min, p  0.05). Hence, at
comparable levels of hyperemic blood flow, the effects of
NOS inhibition were similar.
In the present study, L-NMMA infusion significantly
attenuated the hyperemic response to adenosine 70, but not
to adenosine 140 (where the 8% reduction in myocardial
blood flow failed to reach statistical significance). However,
this does not mean that L-NMMA affects adenosine-
induced vasodilation only at low dose. Indeed, NOS inhi-
bition blunted G by 38% and 25% during adenosine 70 and
140, respectively (p  0.05 for each). The fact that NOS
inhibition had a more marked effect on coronary dilation
during low versus high dose adenosine is consistent with the
data by Hein et al. (22), which demonstrated in an in vitro
porcine coronary artery model, that NO contributes rela-
tively more to adenosine mediated vasodilation at lower
doses of the nucleoside. Since only 20 to 30% of the
hyperemic response to adenosine is blunted by NO antag-
onism in vivo, it is evident the majority of the response is
NO-independent, particularly at higher dose where direct,
smooth muscle relaxation predominates.
Mechanism by which homocysteine impairs coronary
microvascular dilation. It has been previously shown, in
the human peripheral circulation, that NO bioavailability is
decreased in subjects with chronic hyperhomocysteinemia
(6) as well as in acute METH (8,9). In the present study, we
observed a reduction in the coronary microvascular dilator
response to adenosine during METH (Figs. 1 and 2). As
such the data argue in favor of an adverse effect of hyper-
homocysteinemia on NO-mediated vasodilation of the cor-
onary microcirculation. Moreover, our observation, within
the same subjects, that NO-mediated vasodilation of the
brachial artery is impaired during hyperhomocysteinemia
supports the assertion that a systemic reduction in bioavail-
able NO exists after methionine loading. Furthermore, data
obtained in the present study, as noted above, demonstrate
that the coronary microvascular response to adenosine is
NO-dependent especially at lower doses of the drug. Ac-
cordingly, the homocysteine-induced impairment of coro-
nary microvascular dilator response to low-dose adenosine
very likely reflects reduction of NO bioavailability.
Mechanism by which homocysteine reduces NO bio-
availability. The mechanism by which hyperhomocys-
teinemia impairs NO bioavailability is not fully understood.
A plausible mechanism appears to be related to the in-
creased NO destruction as a result of enhanced production
of reactive oxygen species (8,9,26). However, in the present
study, we observed no significant change in iPF2-III (a
plasma marker of oxidant stress), during methionine-
induced hyperhomocysteinemia. A number of potential
explanations exist for the observed lack of increase in
iPF2-III. First, the measurement might not adequately
reflect the intracellular redox status; there may be a lag
between changes in intra- and extracellular redox potential.
Second, the relatively short duration of hyperhomocysteine-
mia (10 h) might not have been long enough to lead to an
increase in the oxidized lipid byproducts that are measured
by the assay. Furthermore, extracellular redox status might
have been affected by the presence of high concentrations of
methionine, which can itself function as a reducing agent
(27).
Another putative mechanism by which hyperhomocys-
teinemia may decrease NO bioavailability is by enhancing
the production of ADMA (which in turn inhibits produc-
tion of NO) (21,28). In the present study, however, we did
not detect an increase in ADMA during transient hyper-
homocysteinemia in healthy subjects with normal fasting
homocysteine concentrations. This may reflect a difference
between subacute METH and naturally occurring chronic
hyperhomocysteinemia. The precise mechanism, by which
hyperhomocysteinemia initiates oxidant stress and reduces
NO bioavailability in the coronary and peripheral circula-
tions cannot be stated based on data acquired in the present
study and therefore requires additional investigation.
Study limitations. While redistribution of coronary micro-
vascular resistance (29) theoretically could make it appear as
if a blunted microvascular response to adenosine in presence
of hyperhomocysteinemia reflected an endothelium-
dependent effect, when in fact it did not, this seems unlikely.
1056 Tawakol et al. JACC Vol. 40, No. 6, 2002
Homocysteine Impairs Coronary Vasodilation in Humans September 18, 2002:1051–8
There is abundant evidence from experiments in the periph-
eral circulation that hyperhomocysteinemia impairs micro-
vascular dilator responses by an NO dependent mechanism
(6,8,9). Moreover, if hyperhomocysteinemia were capable of
causing redistribution of microvascular resistance by an
NO-independent mechanism, then we would anticipate
that the forearm blood flow responses to NO-independent
dilators such as sodium nitroprusside and nitroglycerin
would be impaired in an analogous manner to that observed
for adenosine in the canine study of Jones et al. (29). In fact,
however, dilator responses to these drugs (that is sodium
nitroprusside and nitroglycerin) in the peripheral circulation
are not influenced by hyperhomocysteinemia (6,8,9). Ac-
cordingly, we think it unlikely in the present study that
blunted coronary microvascular response to low dose aden-
osine in the presence of hyperhomocysteinemia reflects
nonspecific redistribution of coronary microvascular resis-
tance.
Clinical implications. This study’s finding that METH is
associated with impaired NO-mediated coronary microvas-
cular dilator function has important clinical implications.
First, it is known that impaired endothelium-dependent
vasodilation of coronary resistance vessels is associated with
exercise-induced myocardial ischemia (30,31). As such, this
study’s finding of impaired coronary microvascular dilator
response suggests a mechanism by which hyperhomocys-
teinemia may cause myocardial ischemia in patients with
coronary atherosclerosis. Second, it is known that plasma
homocysteine concentrations may fluctuate up to 25%
throughout the day, in response to variations in protein
intake (32). As such, this study raises the possibility that the
coronary microvascular dilator response (and hence suscep-
tibility to ischemia) may fluctuate throughout the day, as the
homocysteine concentrations fluctuate. Moreover, the re-
duced nitric oxide bioavailability that results from hyperho-
mocysteinemia might have effects that extend beyond the
symptoms that result from impaired vasodilation. This is
due to the fact that NO plays many important roles that are
relevant to the pathogenesis and pathophysiology of athero-
sclerosis, such as: conferring an important antithrombotic
property on the endothelial surface (by inhibiting the
adhesion, activation, and aggregation of platelets), reducing
the adhesion and emigration of leukocytes into the vessel
wall, and limiting the growth of vascular smooth muscle
cells (33). It follows, then, that hyperhomocysteinemia,
by decreasing nitric oxide bioavailability, may initiate as
well as accelerate the development of obstructive coro-
nary disease and may also aggravate the symptoms that
result from it.
Conclusions. Acute hyperhomocysteinemia induced by
methionine impairs coronary microvascular dilator capacity
by decreasing bioavailable NO, as evidenced by blunted flow
response to low dose adenosine. This extends the observa-
tion of homocysteine-associated blood flow abnormalities to
the coronary circulation, where the most devastating con-
sequences of hyperhomocysteinemia are thought to occur.
These findings underscore the need to determine if lowering
homocysteine with inexpensive and well-tolerated
B-vitamins could impart clinical benefits to patients with
elevated homocysteine concentrations.
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